Incannex Healthcare PSX-001 aligns with Trump Executive Order accelerating psychedelic mental health treatments

Incannex Healthcare Inc.

White House Executive Order (April 18, 2026) directs FDA to prioritize psychedelic compounds with Breakthrough Therapy designations and creates Right to Try pathways.
PSX-001 Phase 2 for GAD: 12.8-point HAM-A reduction vs 3.6 placebo (p<0.0001), 44% response rate, 27% remission rate, no serious adverse events.
Company has over $70M cash, no debt; active U.S. IND; views Executive Order as reducing regulatory and commercial risk for psilocybin class.
PSX-001 targets GAD affecting ~6.8M in U.S. and 280M globally; Phase 2 had single discontinuation across 73 patients.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.